Amgen olpasiran may fill critical treatment gap in lowering Lp(a): GlobalData
This study showed that patients taking 75mg of Olpasiran previously every 12 weeks presented a 40–50% reduction in LP(a)
This study showed that patients taking 75mg of Olpasiran previously every 12 weeks presented a 40–50% reduction in LP(a)
Patients Treated with ARIKAYCE plus macrolide-based background regimen had meaningfully larger improvements in QOL-B respiratory score
This indigenously developed enhanced care technology is designed to continuously monitor and detect early signs of deterioration in a patient's condition
Amgen will be prohibited from leveraging its drug portfolio to disadvantage rivals and will be required to seek prior approval before acquiring related products
Robots make it to the healthcare conference panel, reflecting the future potential of technology
Amneal’s site in Matoda is one of the company’s 12 pharmaceutical manufacturing facilities
Brian Foard will lead the Specialty Care GBU ad interim, effective immediately.
Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia
Dr. Laurent Leksell, Elekta’s Founder and Chairman of the Board, and IAEA’s Director General, Dr. Rafael Mariano Grossi meet in Stockholm to discuss reducing the global cancer burden
Subscribe To Our Newsletter & Stay Updated